Analyzing DBV Technologies (NASDAQ:DBVT) and MeiraGTx (NASDAQ:MGTX)

DBV Technologies (NASDAQ:DBVT) and MeiraGTx (NASDAQ:MGTX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, earnings and institutional ownership.

Institutional & Insider Ownership

71.7% of DBV Technologies shares are held by institutional investors. Comparatively, 67.5% of MeiraGTx shares are held by institutional investors. 0.6% of DBV Technologies shares are held by insiders. Comparatively, 9.7% of MeiraGTx shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Risk and Volatility

DBV Technologies has a beta of 0.73, meaning that its share price is 27% less volatile than the S&P 500. Comparatively, MeiraGTx has a beta of 1.31, meaning that its share price is 31% more volatile than the S&P 500.

Valuation and Earnings

This table compares DBV Technologies and MeiraGTx’s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DBV Technologies	$15.73 million	8.22	-$72.73 million	($0.39)	-1.72
MeiraGTx	$14.02 million	24.68	-$84.03 million	($1.47)	-3.66

DBV Technologies has higher revenue and earnings than MeiraGTx. MeiraGTx is trading at a lower price-to-earnings ratio than DBV Technologies, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations and price targets for DBV Technologies and MeiraGTx, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DBV Technologies	1	0	2	0	2.33
MeiraGTx	0	0	2	0	3.00

DBV Technologies currently has a consensus target price of $5.00, suggesting a potential upside of 646.27%. MeiraGTx has a consensus target price of $25.67, suggesting a potential upside of 377.08%. Given DBV Technologies’ higher probable upside, equities research analysts plainly believe DBV Technologies is more favorable than MeiraGTx.

Profitability

This table compares DBV Technologies and MeiraGTx’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
DBV Technologies	-461.32%	-46.33%	-35.32%
MeiraGTx	-599.47%	-114.33%	-42.56%

Summary

DBV Technologies beats MeiraGTx on 9 of the 13 factors compared between the two stocks.

About DBV Technologies

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs include vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

About MeiraGTx

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.